Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ibrutinib and venetoclax for relapsed CLL

Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

Publish date:: June 29, 2018

Key clinical point: The combination of the targeted agents ibrutinib and venetoclax appears to be safe and shows early efficacy in a phase 2 trial.

Major finding: All of 15 patients analyzed to date have clinical responses to the combination, including 8 complete clinical remissions (without bone marrow confirmation).

Study details: Ongoing open-label, phase 2 randomized trial in patients with relapsed/refractory CLL/SLL.

Disclosures: The study is supported by AbbVie and Janssen, who supplied the drugs and had the right to comment on the presentation. Dr. Niemann has previously disclosed consultancy fees from the companies and others.

Source: Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

Citation:

Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,